Prognostic features of the study group (treated with131I-tositumomab, etoposide, and CTX) and the nonrandomized control group (treated with total-body irradiation, etoposide, and CTX)
| Characteristic . | Study group (n = 52) . | Control group (n = 105)4-150 . |
|---|---|---|
| Median (range) age, y | 47.1 (34-58) | 47.4 (17.4-59.5) |
| Median (range) no. previous regimens | 3 (1-7) | 2 (1-7) |
| Stage4-151 | ||
| I-II | 2 (4) | 14 (14) |
| III | 7 (13) | 20 (19) |
| IV | 43 (83) | 69 (67) |
| Unknown | 0 | 2 |
| Tumor bulk4-151 | ||
| < 5 cm | 48 (94) | 70 (74) |
| > 5 cm | 4 (6) | 25 (26) |
| Unknown | 0 | 10 |
| Splenomegaly | 12 (23)4-151 | 22 (25) |
| No splenomegaly | 40 (77) | 66 (75) |
| Unknown spleen size | 0 | 17 |
| Histologic type | ||
| Indolent | 38 (73) | 44 (42) |
| Aggressive | 14 (27) | 60 (58) |
| Unknown | 0 | 1 |
| Sensitivity to chemotherapy | ||
| Resistant | 10 (19)‡ | 19 (22) |
| Sensitive | 42 (81) | 68 (78) |
| Unknown | 0 | 18 |
| Previous anthracycline therapy | 44 (85%) | 99 (94%) |
| Characteristic . | Study group (n = 52) . | Control group (n = 105)4-150 . |
|---|---|---|
| Median (range) age, y | 47.1 (34-58) | 47.4 (17.4-59.5) |
| Median (range) no. previous regimens | 3 (1-7) | 2 (1-7) |
| Stage4-151 | ||
| I-II | 2 (4) | 14 (14) |
| III | 7 (13) | 20 (19) |
| IV | 43 (83) | 69 (67) |
| Unknown | 0 | 2 |
| Tumor bulk4-151 | ||
| < 5 cm | 48 (94) | 70 (74) |
| > 5 cm | 4 (6) | 25 (26) |
| Unknown | 0 | 10 |
| Splenomegaly | 12 (23)4-151 | 22 (25) |
| No splenomegaly | 40 (77) | 66 (75) |
| Unknown spleen size | 0 | 17 |
| Histologic type | ||
| Indolent | 38 (73) | 44 (42) |
| Aggressive | 14 (27) | 60 (58) |
| Unknown | 0 | 1 |
| Sensitivity to chemotherapy | ||
| Resistant | 10 (19)‡ | 19 (22) |
| Sensitive | 42 (81) | 68 (78) |
| Unknown | 0 | 18 |
| Previous anthracycline therapy | 44 (85%) | 99 (94%) |
Values are numbers (percentages) of patients unless otherwise indicated. All patients entered in both transplant protocols had a good performance status (0-1) according to criteria described by Shipp.21
CTX indicates cyclophosphamide.
Unknown cases are excluded from calculations of percentages.
The patients in the study group with splenomegaly underwent splenectomy before radioimmunotherapy, as required by the study protocol.
Eight patients had primary refractory lymphoma that did not respond to front-line chemotherapy and 2 had chemotherapy-resistant relapses.